Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax

(703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

26693

03/17/2004

REGENERON PHARMACEUTICALS, INC 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591



Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

Loren He	rnandez		(Depositor's name)
Town	Herr	andy	(Signature)
April 16			(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
. 09/577,468	05/24/2000	Vivien W. Wong	REG 142-C	5396

TITLE OF INVENTION: USE OF CILIARY NEUROTROPHIC FACTOR

APPLN. TYPE	SMALL ENTITY	ISSUE F	EE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
nonprovisional	NO	\$1330)	\$0	\$1330	06/17/2004	
EXAMINER ART U		IT CLASS-SUBCLASS					
HAYES, ROB	ERT CLINTON	1647		514-002000			
CFR 1.363).	ce address or indication of "Fo		names of up agents OR, a	ng on the patent front pa to 3 registered patent alternatively, (2) the name	attorneys or Valet	a Gregg, Ph.D.,	
Address form PTO/SB/1	lence address (or Change of (122) attached.	correspondence	firm (having as a member a registered attorney or 2				
☐ "Fee Address" indicat PTO/SB/47; Rev 03-02 Number is required.	tion (or "Fee Address" Indicat or more recent) attached. Use	tion form e of a Customer	attorneys or	agent) and the names of up to 2 registered attorneys or agents. If no name is listed, no will be printed.			
	D RESIDENCE DATA TO B				f assignee data is only appropr	iate when an assignment has	
PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGN	s an assignee is identified be ed to the USPTO or is being	low, no assignee d submitted under se (B	ata will appear o parate cover. Cor B) RESIDENCE:		f assignee data is only appropr IOT a substitute for filing an as COUNTRY) USA	iate when an assignment has signment.	
PLEASE NOTE: Unless been previously submitte (A) NAME OF ASSIGN Regeneron Ph	s an assignee is identified be ed to the USPTO or is being s NEE	low, no assignee d submitted under se (B	ata will appear of parate cover. Cors. RESIDENCE: Tarrytow	on the patent. Inclusion of this form is Notice (CITY and STATE OR Company). New York	COUNTRY)		
PLEASE NOTE: Unless been previously submitted (A) NAME OF ASSIGN Regeneron Phyllease check the appropriat	s an assignee is identified be ed to the USPTO or is being s NEE narmaceuticals, te assignee category or catego	low, no assignee d submitted under se (E Inc. ories (will not be pr	ata will appear of parate cover. Cors. RESIDENCE: Tarrytow	on the patent. Inclusion of this form is Not (CITY and STATE OR Company); New York (and individual)	USA		
PLEASE NOTE: Unless been previously submitted (A) NAME OF ASSIGN Regeneron Ph	s an assignee is identified be ed to the USPTO or is being s NEE narmaceuticals, te assignee category or catego	low, no assignee d submitted under se (E Inc. ories (will not be pr	ata will appear of parate cover. Cores. RESIDENCE: Tarrytow inted on the pate. D. Payment of Fee	on the patent. Inclusion of this form is Not (CITY and STATE OR Company); New York (and individual)	USA Substitution of other private g		
PLEASE NOTE: Unless been previously submitted (A) NAME OF ASSIGN Regeneron Phelease check the appropriate a. The following fee(s) are	s an assignee is identified be ed to the USPTO or is being s NEE narmaceuticals, te assignee category or catego	low, no assignee d submitted under se (E Inc. ories (will not be pr	ata will appear of parate cover. Cores. RESIDENCE: Tarrytow inted on the pater. Payment of Fee Acheck in the Payment by cores.	on the patent. Inclusion of impletion of this form is N (CITY and STATE OR (CITY and STATE OR (CITY), New York (Int); Individual (Int); Int); Individual (Int); Int); Individual (Int); Int); In	USA Corporation or other private genclosed. 38 is attached.	group entity	
PLEASE NOTE: Unless been previously submitted (A) NAME OF ASSIGN Regeneron Phase check the appropriated at The following fee(s) are X-1 Issue Fee	s an assignee is identified be ed to the USPTO or is being so NEE narmaceuticals, te assignee category or categore enclosed:	low, no assignee d submitted under se (E Inc. ories (will not be pr	ata will appear of parate cover. Cores. RESIDENCE: Tarrytow inted on the pater. Payment of Fee Acheck in the Payment by cores.	on the patent. Inclusion of impletion of this form is N (CITY and STATE OR (CITY and STATE OR (CITY), New York (Int); Individual (Int); Int); Individual (Int); Int); Individual (Int); Int); In	USA Corporation or other private genclosed.	group entity	

•	
(Authorized Signature)	(Date)
Valetu Tregg	16 April 2004
NOTE: The Issue Fee and Publication Fee (if	required) will not be accepted from anyone

other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

04/20/2004 HLE444 00000103 09577468

01 FC:1501

1330.00 OP